分组1 - Luzhou Laojiao announced a cash dividend of 45.92 RMB per 10 shares for the fiscal year 2024, totaling approximately 6.759 billion RMB [1] - *ST Huike's control change may terminate as the parties involved have sent a notice to withdraw from the share transfer agreement [2] - Raise Technology plans to acquire 49% of Sichuan Maikelong Vacuum New Materials Co., Ltd. for 231 million RMB, making it a subsidiary [3] 分组2 - Baotai received clinical trial approval for its innovative drug BAT5906, targeting retinal conditions [4] - Huate Dain's subsidiary signed an exclusive distribution agreement for melatonin granules in mainland China, with the product expected to be approved by July 2025 [5] - Jinghe Integration is planning to issue H-shares and list on the Hong Kong Stock Exchange [6] 分组3 - Huatian Technology intends to establish a new subsidiary for advanced packaging with a total investment of 2 billion RMB [7] - Wehua New Materials is in preliminary discussions to acquire controlling interest in Jiangsu Heyutai Chemical Co., Ltd. [8] - Zhongyou Engineering's subsidiary received a project award in Iraq worth approximately 18.032 billion RMB [9] 分组4 - Chipone expects to achieve a revenue of 584 million RMB in Q2 2025, a 49.90% increase quarter-on-quarter [10] - Chang'an Automobile reported a 14.34% year-on-year increase in July sales [10] - Cangge Mining's net profit increased by 38.8% year-on-year in the first half of the year [10]

Group 1 - Nobelpharma's melatonin product, Manlejing®, has been approved for sale in China, specifically for improving sleep difficulties in children aged 6-15 with neurodevelopmental disorders, marking it as the first melatonin formulation approved for this indication in the country [1][2] - Huate Dain has announced that its subsidiary, Dain Health, has signed an exclusive distribution agreement for Manlejing® in mainland China, with an initial term of 10 years [1][2] - The product was previously launched in Japan in 2020 and has shown significant results in reducing sleep latency in clinical trials [2] Group 2 - Other companies, such as Changchun High-tech and Eifang Pharmaceutical, have already established a presence in the market for treating sleep difficulties associated with neurodevelopmental disorders in children [3] - Huate Dain is a leading player in the children's pharmaceutical health sector in China, with its main revenue and profit sources coming from its subsidiary, Dain Pharmaceutical, which focuses on the development, production, and marketing of children's medications [3]

Group 1 - Luzhou Laojiao announced a cash dividend of 45.92 RMB per 10 shares for the 2024 fiscal year, totaling approximately 6.759 billion RMB [1] - The dividend will be distributed to all shareholders registered by the close of trading on August 7, 2025, with the ex-dividend date set for August 8, 2025 [1] Group 2 - Huatian Technology plans to establish a wholly-owned subsidiary, Nanjing Huatian Advanced Packaging Co., Ltd., with a total registered capital of 2 billion RMB to engage in 2.5D/3D integrated circuit packaging and testing [2] - The investment will be shared among its subsidiaries, with Huatian Jiangsu contributing 1 billion RMB (50%), Huatian Kunshan 665 million RMB (33.25%), and Advanced No. 1 335 million RMB (16.75%) [2] Group 3 - China Petroleum Engineering's subsidiary received a project award letter for a seawater pipeline project in Iraq, valued at approximately 18.032 billion RMB (2.524 billion USD) [3] - Successful signing and implementation of the project could enhance the company's market position in Iraq and the Middle East, positively impacting revenue and profit over the next 4-5 years [3] Group 4 - Jinghe Integrated is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with relevant intermediaries [4] - The H-share issuance will not change the company's controlling shareholder or actual controller [4] Group 5 - Huate Dain's subsidiary signed an exclusive distribution agreement for melatonin granules (Manlejing®) with Japan's Nobori Pharmaceutical, set to be approved for sale in mainland China by July 2025 [5] - This product will be the first melatonin formulation approved for treating sleep difficulties in children aged 6-15 with neurodevelopmental disorders in China [5] Group 6 - Baotai announced that its innovative drug BAT5906, a humanized monoclonal antibody injection, received clinical trial approval for new indications related to retinal conditions [6] - The drug has completed various phases of clinical trials for other indications and is preparing for further studies [6] Group 7 - Chipone Technology expects a revenue of approximately 584 million RMB for the second quarter, reflecting a quarter-on-quarter growth of 49.9% [7] - Qianli Technology reported July automobile sales of 10,200 units, a year-on-year increase of 142.34% [7] Group 8 - Hanma Technology's truck sales in July reached 956 units, marking a year-on-year growth of 42.69% [8] - Tianyi New Materials anticipates a net loss of 190 million to 240 million RMB for the first half of the year [8] Group 9 - Yabian Chemical signed a supply strategic agreement with Heng Rui Pharmaceutical [9] - Weisheng Information won procurement projects totaling 110 million RMB from South Grid and State Grid [9] - Dongjie Intelligent received a procurement order from PTT LOGISTICS SDN BHD worth approximately 62.5 million RMB [9]

每经AI快讯，有投资者在投资者互动平台提问：近期二级市场行情火爆，贵公司股价却萎靡不振，坊 间传闻贵公司半年度业绩不佳，一些消息灵通的大户提前撤退，将筹码抛售给不明真相的散户。请问是 否属实？ 华特达因（000915.SZ）8月1日在投资者互动平台表示，公司2025年半年度报告定于2025年8月8日披 露，业绩情况请您以公司披露的《2025年半年度报告》为准。 （文章来源：每日经济新闻） ...

Core Viewpoint - Huate Dain (000915.SZ) has signed an exclusive distribution agreement with Nobelpharma Co., Ltd for melatonin granules (brand name: Manlejing®) in mainland China, marking a significant step in addressing the treatment gap for sleep difficulties in children with neurodevelopmental disorders [1] Group 1 - Huate Dain's subsidiary, Beijing Dain Kangjian Pharmaceutical Co., Ltd, will be the exclusive distributor for Manlejing® in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - The product is set to be approved for market launch in China by July 2025, targeting children aged 6-15 with sleep difficulties [1] - This agreement allows Huate Dain to manage the import, marketing, and sales of the product, fulfilling a critical clinical need in the domestic market [1]

Group 1 - The company Huate Dain announced that its subsidiary Beijing Dain Kangjian has reached an agreement with Japan's Nobel Pharma Co., Ltd. for the exclusive general distribution of melatonin granules (Manlejing®) in mainland China [1] - Dain Kangjian will be the exclusive general distributor of this product in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - The product is expected to be approved for sale in China by July 2025 and is the first melatonin formulation approved for treating sleep difficulties in children aged 6-15 with neurodevelopmental disorders in the country [1]

Core Viewpoint - The company Huate Dain (000915.SZ) has reached an agreement with Japan's Nobel Pharma Co., Ltd. for the exclusive distribution of melatonin granules (Manlejing®) in mainland China, marking a significant development in the pediatric sleep disorder treatment market [1] Company Summary - Huate Dain's subsidiary, Beijing Dain Kangjian, will serve as the exclusive distributor for the melatonin product in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - The product is set to be approved for market launch in China by July 2025 [1] - Manlejing® is the first melatonin formulation approved in China for treating sleep difficulties in children aged 6-15 with neurodevelopmental disorders [1] - This product represents the first instance of a melatonin-based substance receiving marketing authorization as a pharmaceutical in China [1]

Core Viewpoint - The company Huate Dain (000915) has reached an exclusive distribution agreement for melatonin granules (Manlejing) with Japan's Nobel Pharma, marking a significant development in the pediatric sleep disorder treatment market in China [1] Group 1: Company Developments - Huate Dain's subsidiary, Beijing Dain Kangjian, will serve as the exclusive distributor for the melatonin product in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - The product is set to be approved for market release in China by July 2025 [1] Group 2: Product Significance - Manlejing is the first melatonin formulation approved in China for treating sleep difficulties in children aged 6-15 with neurodevelopmental disorders [1] - This product represents the first instance of a melatonin-based substance receiving drug approval in China [1]

Group 1 - The company announced that its subsidiary, Beijing Dainkang Health Pharmaceutical Co., Ltd., has reached an agreement with Japan's Nobori Pharmaceutical Co., Ltd. for the exclusive general distribution of melatonin granules (brand name: Manlejing) in mainland China [1] - According to the agreement, Dainkang Health will become the exclusive distributor of Nobori's melatonin granules in mainland China, responsible for the product's import, marketing, and sales [1]

Group 1 - The core point of the article is that Huate Dain (000915.SZ) has reached an agreement with Japan's Noborin Pharmaceutical Co., Ltd. for exclusive distribution rights of melatonin granules (brand name: Manlejing®) in mainland China [1] - The agreement stipulates that Dain Kangjian will be the exclusive distributor for Noborin's melatonin granules in mainland China, responsible for the import, marketing, and sales of the product [1]